This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bacon, T. H.
Right arrow Articles by Sutton, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacon, T. H.
Right arrow Articles by Sutton, D.

 Previous Article  |  Next Article 

Clinical Microbiology Reviews, January 2003, p. 114-128, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.114-128.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy

Teresa H. Bacon,1* Myron J. Levin,2 Jeffry J. Leary,3 Robert T. Sarisky,3 and David Sutton3

GlaxoSmithKline Consumer Healthcare, Weybridge, Surrey KT15 0DE, United Kingdom,1 Pediatric Infectious Diseases, University of Colorado Health Sciences Center, Denver, Colorado 80262,2 Antimicrobial and Host Defense Center of Excellence for Drug Discovery, GlaxoSmithKline Pharmaceuticals, Collegeville, Pennsylvania 194263

Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections. In spite of the distribution of over 2.3 x 106 kg of these nucleoside analogues, the prevalence of acyclovir resistance in herpes simplex virus isolates from immunocompetent hosts has remained stable at approximately 0.3%. In immuncompromised patients, in whom the risk for developing resistance is much greater, the prevalence of resistant virus has also remained stable but at a higher level, typically 4 to 7%. These observations are examined in the light of characteristics of the virus, the drugs, and host factors.

* Corresponding author. Mailing address: GlaxoSmithKline Consumer Healthcare, St George's Ave., Weybridge, Surrey KT15 0DE, United Kingdom. Phone: 44 1932 822185. Fax: 44 1932 822139. E-mail: teresa.h.bacon{at}gsk.com.

Clinical Microbiology Reviews, January 2003, p. 114-128, Vol. 16, No. 1
0893-8512/03/$08.00+0     DOI: 10.1128/CMR.16.1.114-128.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Tchesnokov, E. P., Obikhod, A., Massud, I., Lisco, A., Vanpouille, C., Brichacek, B., Balzarini, J., McGuigan, C., Derudas, M., Margolis, L., Schinazi, R. F., Gotte, M. (2009). Mechanisms Associated with HIV-1 Resistance to Acyclovir by the V75I Mutation in Reverse Transcriptase. J. Biol. Chem. 284: 21496-21504 [Abstract] [Full Text]  
  • Martinez, V., Caumes, E., Eisenhut, M., Nagot, N., Weiss, H., Van de Perre, P. (2007). HSV Therapy and HIV-1 Reduction. NEJM 356: 2323-2324 [Full Text]  
  • Pesola, J. M., Coen, D. M. (2007). In vivo fitness and virulence of a drug-resistant herpes simplex virus 1 mutant. J. Gen. Virol. 88: 1410-1414 [Abstract] [Full Text]  
  • Liu, S., Knafels, J. D., Chang, J. S., Waszak, G. A., Baldwin, E. T., Deibel, M. R. Jr., Thomsen, D. R., Homa, F. L., Wells, P. A., Tory, M. C., Poorman, R. A., Gao, H., Qiu, X., Seddon, A. P. (2006). Crystal Structure of the Herpes Simplex Virus 1 DNA Polymerase. J. Biol. Chem. 281: 18193-18200 [Abstract] [Full Text]  
  • Williams-Aziz, S. L., Hartline, C. B., Harden, E. A., Daily, S. L., Prichard, M. N., Kushner, N. L., Beadle, J. R., Wan, W. B., Hostetler, K. Y., Kern, E. R. (2005). Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro. Antimicrob. Agents Chemother. 49: 3724-3733 [Abstract] [Full Text]  
  • Andrei, G., Balzarini, J., Fiten, P., De Clercq, E., Opdenakker, G., Snoeck, R. (2005). Characterization of Herpes Simplex Virus Type 1 Thymidine Kinase Mutants Selected under a Single Round of High-Dose Brivudin. J. Virol. 79: 5863-5869 [Abstract] [Full Text]  
  • MacDougall, C., Guglielmo, B. J. (2004). Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53: 899-901 [Abstract] [Full Text]  
  • Corey, L., Wald, A., Patel, R., Sacks, S. L., Tyring, S. K., Warren, T., Douglas, J. M. Jr., Paavonen, J., Morrow, R. A., Beutner, K. R., Stratchounsky, L. S., Mertz, G., Keene, O. N., Watson, H. A., Tait, D., Vargas-Cortes, M., the Valacyclovir HSV Transmission Study Group, (2004). Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. NEJM 350: 11-20 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»